Flexibility helps bring chemical weapons conference to a close despite tensions
2022 reminded us that SARS-CoV-2 isn’t the only viral threat
Russia’s invasion disrupted drug discovery, but Ukrainian scientists are carrying on
Gene therapies, novel psoriasis drugs, and a Botox rival are among notable green-lit products
Biotech funding woes dragged on, while employment stayed strong
Although mifepristone and misoprostol have been around for decades, overturning <i>Roe v. Wade </i>brought renewed.
Even with the field’s multiple setbacks, Alzheimer’s experts still count 2022 as an exciting year
A flurry of advances in clinical trials was tempered by problems and slowdowns